Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.23% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Top 29 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$19M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -543%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $7M covers the $2M due within a year 3.9× over. Scheduled principal only (excludes interest & revolver draws). As of 2024-03-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M 100.0% | $3.7M 100.0% | $1.2M 100.0% | — | — | $873K 100.0% | $1.4M 100.0% | $7.7M 100.0% | — | — |
| Cost of Revenue | $7.4M 96.7% | $5.4M 144.9% | $2.5M 212.8% | $555K | — | — | — | — | — | — |
| Gross Profit | $252K 3.3% | -$1.7M -44.9% | -$1.3M -112.8% | -$555K | — | — | — | — | — | — |
| Research & Development | $10.2M 133.4% | $16.9M 455.0% | $24.4M 2102.1% | $16.8M | $11.8M | $12.6M 1445.4% | $10.6M 766.1% | $3.9M 50.9% | $4.6M | $4.4M |
| Selling, General & Admin | $19.1M 248.1% | $26.0M 702.2% | $37.3M 3221.5% | $34.7M | $18.4M | $10.5M 1199.1% | $8.9M 639.0% | $6.9M 88.7% | $5.3M | $6.6M |
| Total Operating Expenses | $29.3M 381.5% | $42.9M 1157.2% | $61.7M 5323.6% | $51.5M | $40.7M | — | — | — | — | — |
| Operating Income | -$29.0M -378.2% | -$44.5M -1202.1% | -$63.0M -5436.2% | -$52.1M | -$40.7M | -$22.2M -2544.6% | -$18.1M -1305.1% | -$3.1M -39.6% | $9.9M | -$11.1M |
| Interest Expense | $3.5M 45.8% | $3.0M 81.5% | $2.9M 251.3% | $30K | $775K | $642K 73.5% | $31K 2.2% | $2K 0.0% | — | $15K |
| Other Income (Expense), net | -$5.3M -68.9% | -$3.9M -106.4% | -$1.3M -111.1% | -$7.3M | -$3.4M | -$661K -75.7% | -$2.0M -140.6% | -$3.5M -45.3% | -$773K | -$7.0M |
| Pretax Income | -$34.3M -447.1% | -$48.5M -1308.5% | -$64.3M -5547.5% | -$59.4M | -$44.1M | -$22.9M -2620.3% | -$20.1M -1445.7% | -$6.6M -85.3% | — | $18.0M |
| Income Tax Expense | — | — | — | — | — | — | -$154K -11.1% | — | — | — |
| Net Income | -$33.2M -433.0% | -$46.6M -1258.4% | -$60.2M -5197.8% | -$55.8M | -$43.2M | -$22.9M -2620.3% | -$19.9M -1434.6% | -$6.6M -84.9% | -$10.7M | -$18.0M |
| Per Share | ||||||||||
| EPS (Basic) | $-4.01 | $-13.77 | $-1.82 | $-1.86 | $-1.68 | $-1.27 | — | $-0.77 | — | $-3.01 |
| EPS (Diluted) | $-4.01 | $-13.77 | $-1.82 | $-1.86 | — | — | — | $-0.77 | — | $-3.01 |
| Weighted Avg Shares (Basic) | 8.3M | 3.4M | 33.2M | 30.0M | 25.7M | 18.01B | — | 8.5M | — | 6.0M |
| Weighted Avg Shares (Diluted) | 8.3M | 3.4M | 33.2M | 30.0M | — | — | — | 8.5M | — | 6.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| XAIR | $36M | — | — | 4.7× | 107% | 3.3% | -433% | -543% | -543% | — | 28 |
Peers = companies sharing XAIR's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 10-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 10-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | — | 212.8 | 144.9 | 96.7 |
| Gross Profit | — | — | — | — | — | -112.8 | -44.9 | 3.3 |
| R&D | 50.9 | 766.1 | 1445.4 | — | — | 2102.1 | 455.0 | 133.4 |
| SG&A | 88.7 | 639.0 | 1199.1 | — | — | 3221.5 | 702.2 | 248.1 |
| Operating Income | -39.6 | -1305.1 | -2544.6 | — | — | -5436.2 | -1202.1 | -378.2 |
| Income Tax | — | -11.1 | — | — | — | — | — | — |
| Net Income | -84.9 | -1434.6 | -2620.3 | — | — | -5197.8 | -1258.4 | -433.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on XAIR: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.